Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (noting the input metadata reference to Insight Molecular Diagnostics Inc. appears to be a discrepancy, as the filing text explicitly identifies OncoCyte Corporation) on July 17, 2019. The report details the outcomes of the company's annual meeting of shareholders held on that date.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
The following material actions were approved by shareholders at the annual meeting:
- Equity Incentive Plan Amendment: Shareholders approved an amendment to the 2018 Equity Incentive Plan, making an additional 6,000,000 shares of common stock available for equity awards.
- Bylaws Amendment: Shareholders approved an amendment to the Bylaws to increase the number of authorized directors from a minimum of four and maximum of seven to a minimum of six and maximum of ten.
- Director Elections: Seven directors were elected to serve until the next annual meeting.
- Accountant Ratification: The appointment of OUM & Co. LLP as the independent registered public accountants for the fiscal year ending December 31, 2019, was ratified.
Shareholder Voting Results
As of the record date (May 30, 2019), there were 51,972,830 shares outstanding. Approximately 78.7% of voting power was represented at the meeting.
| Matter | Votes For | Votes Against | Abstentions |
|---|---|---|---|
| Ratification of Accountants | 40,704,144 | 152,511 | 43,861 |
| Bylaws Amendment | 30,385,285 | 91,591 | 20,289 |
| Equity Incentive Plan Amendment | 28,747,335 | 1,651,032 | 98,798 |
Note: There were 10,403,351 broker non-votes regarding the election of directors, the Bylaws Amendment, and the Equity Incentive Plan Amendment.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements disclaiming any obligation to update future projections. It references the company's most recent Form 10-K for a detailed discussion of risk factors that could cause actual results to differ materially from anticipated results. No specific new risks or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the impact of the 6,000,000 share increase in the Equity Incentive Plan on potential future dilution.
- Review the Bylaws Amendment to understand the new flexibility in board size (6-10 directors).
- Confirm the audit firm (OUM & Co. LLP) and review their independence disclosures in the full proxy statement.
- Check the director election results for any significant "withheld" votes, particularly for nominees Andrew Arno, Andrew J. Last, and Cavan Redmond, who received over 1.2 million withheld votes each.